Loading…
A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients
The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 female...
Saved in:
Published in: | American journal of hypertension 2000-04, Vol.13 (S2), p.144A-144A |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 144A |
container_issue | S2 |
container_start_page | 144A |
container_title | American journal of hypertension |
container_volume | 13 |
creator | Sanjuliani, A.F. Barroso, S.G. Fagundes, V.G.A. Rodrigues, M.L.G. Moulin, C.S. Netto, J.F. Francischetti, E.A. |
description | The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p < 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p < 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine. |
doi_str_mv | 10.1016/S0895-7061(00)00620-8 |
format | article |
fullrecord | <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_proquest_journals_1038141855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2753710621</sourcerecordid><originalsourceid>FETCH-LOGICAL-i665-2382f37646537013afad1c18b85664717f135eda159963f6421c3037d23b82973</originalsourceid><addsrcrecordid>eNo9j01LxDAYhIMouH78BCHgRcFq3qT5qDcRXYV1hVVQvJRs-xaj3bQmWdm9-8OtKJ6GGR5mGEIOgJ0CA3X2wEwhM80UHDF2zJjiLDMbZARFDpnmXG6S0T-yTXZifGOM5UrBiHxdMKPP6V236ryrnUdqfU3tou1q1_9YbBqsUqSdp-2Q1LQPXeNaPKHL4LwNaxoHdLmguKoCJjdwPw2VbbvgKup8su84CO3mGJG-rnsMCX10n0h7mxz6FPfIVmPbiPt_ukser68eL2-yyf349vJikjmlZMaF4Y3QKldSaAbCNraGCszcSKVyDboBIbG2IItCiUblHCrBhK65mBteaLFLDn9rhwsfS4ypfOuWwQ-LJTBhIAcj5UBlv5SLCVdlH9xieFna8F4qLbQsb55fyqnmk9l49lROxTfP7XJm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038141855</pqid></control><display><type>article</type><title>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</title><source>Oxford Journals Online</source><creator>Sanjuliani, A.F. ; Barroso, S.G. ; Fagundes, V.G.A. ; Rodrigues, M.L.G. ; Moulin, C.S. ; Netto, J.F. ; Francischetti, E.A.</creator><creatorcontrib>Sanjuliani, A.F. ; Barroso, S.G. ; Fagundes, V.G.A. ; Rodrigues, M.L.G. ; Moulin, C.S. ; Netto, J.F. ; Francischetti, E.A.</creatorcontrib><description>The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p < 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p < 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/S0895-7061(00)00620-8</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>caloric intake ; obesity ; Sodium excretion</subject><ispartof>American journal of hypertension, 2000-04, Vol.13 (S2), p.144A-144A</ispartof><rights>Copyright Nature Publishing Group Apr 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Sanjuliani, A.F.</creatorcontrib><creatorcontrib>Barroso, S.G.</creatorcontrib><creatorcontrib>Fagundes, V.G.A.</creatorcontrib><creatorcontrib>Rodrigues, M.L.G.</creatorcontrib><creatorcontrib>Moulin, C.S.</creatorcontrib><creatorcontrib>Netto, J.F.</creatorcontrib><creatorcontrib>Francischetti, E.A.</creatorcontrib><title>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p < 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p < 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.</description><subject>caloric intake</subject><subject>obesity</subject><subject>Sodium excretion</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNo9j01LxDAYhIMouH78BCHgRcFq3qT5qDcRXYV1hVVQvJRs-xaj3bQmWdm9-8OtKJ6GGR5mGEIOgJ0CA3X2wEwhM80UHDF2zJjiLDMbZARFDpnmXG6S0T-yTXZifGOM5UrBiHxdMKPP6V236ryrnUdqfU3tou1q1_9YbBqsUqSdp-2Q1LQPXeNaPKHL4LwNaxoHdLmguKoCJjdwPw2VbbvgKup8su84CO3mGJG-rnsMCX10n0h7mxz6FPfIVmPbiPt_ukser68eL2-yyf349vJikjmlZMaF4Y3QKldSaAbCNraGCszcSKVyDboBIbG2IItCiUblHCrBhK65mBteaLFLDn9rhwsfS4ypfOuWwQ-LJTBhIAcj5UBlv5SLCVdlH9xieFna8F4qLbQsb55fyqnmk9l49lROxTfP7XJm</recordid><startdate>200004</startdate><enddate>200004</enddate><creator>Sanjuliani, A.F.</creator><creator>Barroso, S.G.</creator><creator>Fagundes, V.G.A.</creator><creator>Rodrigues, M.L.G.</creator><creator>Moulin, C.S.</creator><creator>Netto, J.F.</creator><creator>Francischetti, E.A.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200004</creationdate><title>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</title><author>Sanjuliani, A.F. ; Barroso, S.G. ; Fagundes, V.G.A. ; Rodrigues, M.L.G. ; Moulin, C.S. ; Netto, J.F. ; Francischetti, E.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i665-2382f37646537013afad1c18b85664717f135eda159963f6421c3037d23b82973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>caloric intake</topic><topic>obesity</topic><topic>Sodium excretion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanjuliani, A.F.</creatorcontrib><creatorcontrib>Barroso, S.G.</creatorcontrib><creatorcontrib>Fagundes, V.G.A.</creatorcontrib><creatorcontrib>Rodrigues, M.L.G.</creatorcontrib><creatorcontrib>Moulin, C.S.</creatorcontrib><creatorcontrib>Netto, J.F.</creatorcontrib><creatorcontrib>Francischetti, E.A.</creatorcontrib><collection>Istex</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanjuliani, A.F.</au><au>Barroso, S.G.</au><au>Fagundes, V.G.A.</au><au>Rodrigues, M.L.G.</au><au>Moulin, C.S.</au><au>Netto, J.F.</au><au>Francischetti, E.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>2000-04</date><risdate>2000</risdate><volume>13</volume><issue>S2</issue><spage>144A</spage><epage>144A</epage><pages>144A-144A</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><coden>AJHYE6</coden><abstract>The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p < 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p < 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1016/S0895-7061(00)00620-8</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0895-7061 |
ispartof | American journal of hypertension, 2000-04, Vol.13 (S2), p.144A-144A |
issn | 0895-7061 1941-7225 |
language | eng |
recordid | cdi_proquest_journals_1038141855 |
source | Oxford Journals Online |
subjects | caloric intake obesity Sodium excretion |
title | A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T07%3A13%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A087:%20Moxonidine%20and%20amlodipine%20effects%20on%20lipid%20profile,%20urinary%20sodium%20excretion%20and%20caloric%20intake%20in%20obese%20hypertensive%20patients&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Sanjuliani,%20A.F.&rft.date=2000-04&rft.volume=13&rft.issue=S2&rft.spage=144A&rft.epage=144A&rft.pages=144A-144A&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1016/S0895-7061(00)00620-8&rft_dat=%3Cproquest_istex%3E2753710621%3C/proquest_istex%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i665-2382f37646537013afad1c18b85664717f135eda159963f6421c3037d23b82973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1038141855&rft_id=info:pmid/&rfr_iscdi=true |